Naim Alkhouri

Chief Academic Officer (CAO) at Summit Clinical Research. Director of the Steatotic Liver Program. Clinical Research Institute of Ohio/ North Shore Gastro.

[Naim Alkhouri @AlkhouriNaim]

@MWeintraubMD @Ali_Aminian_MD Sorry to say this but this is not a good paper. How do you go from 140,000 in the initial sample to 146 patients in each group in the per protocol analysis?!! Moreover, not many patients received the full obesity dose for sema/ Tirzepatide.

[Naim Alkhouri @AlkhouriNaim]

Kicking off the Global Think Tank on Steatotic Liver Disease #SLD in beautiful Barcelona. This is the “most interactive meeting” in hepatology. @schattenbergJ @scottisaacsmd @FattyLiverA @PerspectumGroup @Echosens @MadrigalPharma

[Naim Alkhouri @AlkhouriNaim]

Great to see this great summary of our trial with Resmetirom in MASH cirrhosis. @MadrigalPharma @Pinnacle_TX @NoureddinMD @scottisaacsmd @Echosens @Boehringer @FattyLiverA @LiverArizona @NorthshoreGI @docbinujohn @juanpabloarab

[S A I ™️ @WallStSai]

Congratulations @MadrigalPharma $MDGL on the great MASH Cirrhosis F4C results and @AlkhouriNaim for great presentation at EASL2025!

F4C Key Clinical Highlights:

•>50% of patients achieved a ≥25% sustained reduction in liver stiffness (VCTE), a marker associated with reduced risk of decompensation.
•35% showed fibrosis regression from F4 to a profile consistent with F3.
•CSPH risk dropped from 35% to 15% over 2 years (Baveno and modified Baveno criteria).
•ALT reduced by 20%, GGT by 36%, and Pro-C3 by 40% at Year 2.
•Significant improvements in CK-18 (–321 µg/L), adiponectin (+42%), and atherogenic lipids including LDL-C, ApoB, triglycerides, and Lp(a).
•Liver volume decreased by 22–25%, with corresponding spleen volume reductions linked to improved platelet counts and portal pressure markers.
•Only 6/122 patients decompensated over two years, primarily those with advanced baseline disease.
•Favorable safety profile with no drug-related serious adverse events and a low discontinuation rate (2.5%).

Bottom Line for Clinicians: These data suggest resmetirom may be a disease-modifying option for MASH cirrhosis

$XBI $IBB $AKRO $ETNB $ALT #MASH

[Naim Alkhouri @AlkhouriNaim]

@NoureddinMD presenting the most important data at the @EASLnews #ILC2025 meeting. Reversal of cirrhosis is possible!! Amazing data. @Pinnacle_TX @pgholam @LiverArizona @NorthshoreGI @OHIOLIVER @AlinaAllenMD @FattyLiverA

[Naim Alkhouri @AlkhouriNaim]

@NoureddinMD presenting the most important data at the @EASLnews #ILC2025 meeting. Reversal of cirrhosis is possible!! Amazing data. @Pinnacle_TX @pgholam @LiverArizona @NorthshoreGI @OHIOLIVER @AlinaAllenMD @FattyLiverA

[Naim Alkhouri @AlkhouriNaim]

It was great seeing some old colleagues at @DDWMeeting . All doing exceptionally great things. Also nice to see all the new drugs for liver diseases making an impact:) @atreja @binuj @MadrigalPharma @Pinnacle_TX @geneyim @novonordisk @NorthshoreGI @NoureddinMD

[Naim Alkhouri @AlkhouriNaim]

First time presenting at the Asembia pharmacy meeting. @asembiarx . Good to hear all the issues related to access. @MadrigalPharma @novonordisk @Echosens @Pinnacle_TX @NoureddinMD #MASLD @NorthshoreGI @FattyLiverA

[Naga Chalasani @nagachalasani]

Early experience with resmetirom to treat MASH by @IUGastro https://t.co/IEaAc23PFX
-High d/c rate due to GI AEs
-Need close f/u early to manage GI AEs
-Certainly not "prescribe & forget" like DAAs
@MadrigalPharma @rajVuppaLanchi @AlkhouriNaim @MazenNoureddin @ebtapper

[Naim Alkhouri @AlkhouriNaim]

@WAleyadeh @NoureddinMD @juanpabloarab @MarcoArreseMD @Pinnacle_TX @MadrigalPharma @Echosens @Boehringer You can just adjust the prevalence in your settings. Lmk what you think.

[Naim Alkhouri @AlkhouriNaim]

Try out the ALADDIN calculator and provide feedback on its performance. So proud of the team, Dr. Winston Dunn, @NoureddinMD @juanpabloarab @MarcoArreseMD @Pinnacle_TX. We will use in our clinics and trials soon. @MadrigalPharma @Echosens @Boehringer

https://t.co/TBIBZuL8JH

[Naim Alkhouri @AlkhouriNaim]

Lovely experience presenting at the #USCAP2025 pathology meeting in Boston. Met some amazing hepato-pathologists. Thank you Dr. Maha Guindi for the invitation. @HistoIndex @juanpabloarab @LiverArizona @Pinnacle_TX @FattyLiverA

[Naim Alkhouri @AlkhouriNaim]

One of the best reviews out there on GLP1RAs for MASLD. I'm biased of course, lol. @NoureddinMD @SonalKumarMD @novonordisk @EliLillyandCo @Boehringer @LiverArizona @FattyLiverA @LiverSaver @AmerGastroAssn https://t.co/Gpxvk51NFS

[Naim Alkhouri @AlkhouriNaim]

Very excited to present at the premier Pathology meeting in the US #USCAP2025 #liverpath @LiverArizona @allende_d @NoureddinMD @HistoIndex @Echosens @Pinnacle_TX @LiverSaver @FattyLiverA

[Hans Popper Hepatopathology Society @LiverPath_HPHS]

🍩Dr Naim Alkhouri @AlkhouriNaim will give us an update on steatotic liver disease nomenclature

⚙️Dr Daniela Allende @Allende_DS will show us how pathologic interpretation of steatotic liver disease is evolving

#USCAP2025 #liverpath

[Naim Alkhouri @AlkhouriNaim]

Dr. Julio Gutierrez giving a master class on MASH future drugs. The future is bright:) @MadrigalPharma @novonordisk @sagimet @akerotx @NoureddinMD @LiverArizona @Boehringer @JVLazarus @BostonPharm @SonalKumarMD @scottisaacsmd

[Naim Alkhouri @AlkhouriNaim]

Kicking off the Desert Liver Conference DLC2025 with the NIT Summit. So happy to give the podium to different NIT companies to share their perspectives. Laurent Sandrin, the inventor of Fibroscan, giving an update. @Echosens @NoureddinMD @LiverArizona @Pinnacle_TX

[Naim Alkhouri @AlkhouriNaim]

Thank you @scottisaacsmd for highlighting our paper on cT1 prediction of histology response in MASH @PerspectumGroup .
@LiverArizona @FattyLiverA @geneyim @VCU_Liver @NoureddinMD

[Scott Isaacs @scottisaacsmd]

Congratulations to the authors featured on the @JHepatology cover! Their stunning LiverMultiScan image highlights groundbreaking findings: reductions in cT1 and PDFF liver fat content reflect treatment-induced histological improvements in MASH. A big step forward in non-invasive liver monitoring and response to treatments.👏 #MASH
https://t.co/pIlpSz0qvp

[Naim Alkhouri @AlkhouriNaim]

How to design trials for MetALD; the most relevant question at the @AASLDtweets ETC. @NoureddinMD giving an outstanding presentation.
@EASLedu @NASH_and_coffee @juanpabloarab @liver4kids @LiverArizona @MadrigalPharma @Boehringer @GalectinGALT

[Naim Alkhouri @AlkhouriNaim]

Dr. Gene Im discussing definitions for MetALD! It’s ironic that this meeting about obesity and alcohol is in Las Vegas:) #AALSDETC @AASLDtweets @juanpabloarab @JVLazarus @NoureddinMD @TheLiverPost @LiverArizona @VCU_Liver @liver4kids @FattyLiverA @LiverSaver @novonordisk

[Naim Alkhouri @AlkhouriNaim]

Kicking off the @AASLDtweets ETC on SLD! Animal
Models for MetALD are key for drug development. @NoureddinMD @juanpabloarab @MadrigalPharma @EASLedu @NASH_and_coffee

[Naim Alkhouri @AlkhouriNaim]

Giving lectures in China has a different feeling:) despite the language barrier, the attendees were very engaged! Amazing food and friends as well:) @LiverArizona @NoureddinMD @Pinnacle_TX @betelm @TonyVilliotti @NickEngelke_ @SonalKumarMD